CoChat

Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background: Opioids are effective for treating acute pain but have safety, tolerability, and addiction concerns while non-opioid analgesics have limited efficacy. Suzetrigine, an oral, non-opioid, small molecule, selectively inhibits the voltage-gated sodium channel 1.8 (Na V 1.8) and has potential to provide efficacious and safe relief for acute pain, without addiction concerns. Methods: To evaluate suzetrigine for treatment of acute pain, we conducted two phase 3, randomized, double-blind, placebo- and active-controlled trials in adults with moderate-to-severe acute pain on the verbal categorical rating scale and ≥4 on the numeric pain rating scale (NPRS) after abdominoplasty (N=1118) or bunionectomy (N=1073). After surgery, participants were randomized to suzetrigine (100mg then 50mg every 12hrs), hydrocodone bitartrate/acetaminophen (HB/APAP; 5/325mg every 6hrs), or placebo for 48 hours. The primary endpoint was time-weighted sum of the pain intensity difference in NPRS from 0-48hrs (SPID48) versus placebo. Key secondary endpoints were SPID48 versus HB/APAP and time to ≥2-point reduction in NPRS from baseline versus placebo. Results: The primary endpoint was achieved in both trials with suzetrigine demonstrating statistically significant and clinically meaningful reduction in pain versus placebo. The least squares mean difference in SPID48 between suzetrigine and placebo was 48.4 (95%CI:33.6,63.1; P <0.0001) after abdominoplasty and 29.3 (95%CI:14.0,44.6; P =0.0002) after bunionectomy. Neither trial achieved the first key secondary endpoint of superiority of suzetrigine versus HB/APAP on SPID48. For the second key secondary endpoint of time to ≥2-point reduction in NPRS, suzetrigine had a more rapid onset of clinically meaningful pain relief versus placebo after abdominoplasty (119min versus 480mins, nominal P<0.0001) and bunionectomy (240mins versus 480mins, nominal P=0.0016). Adverse events (AEs) were similar to those seen in post-surgical settings. Conclusions: As compared with placebo, suzetrigine reduced moderate-to-severe acute pain over 48 hours after abdominoplasty or bunionectomy. Pain reduction with suzetrigine was similar to that with HB/APAP. Suzetrigine was associated with adverse events that were mild to moderate in severity. Clinicaltrials.gov Registration: NCT05558410 and NCT05553366

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/aln.0000000000005460

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Participants in the acute pain trials of suzetrigine. The figure includes participants in the acute pain randomized control trials of suzetrigine. (A) Participants in the abdominoplasty trial. (B) Participants in the bunionectomy trial. HB/APAP, hydrocodone bitartrate/acetaminophen.
Fig. 1. Participants in the acute pain trials of suzetrigine. The figure includes participants in the acute pain randomized control trials of suzetrigine. (A) Participants in the abdominoplasty trial. (B) Participants in the bunionectomy trial. HB/APAP, hydrocodone bitartrate/acetaminophen.CC BY-NC-ND · PubMed Central
Fig. 2. Mean PID over time. The figure includes participants who were randomized and received at least one dose of study drug. Participants were analyzed according to their randomized treatment. (A and B) Participants included in the prespecified analysis with rescue imputation (effect of suzetrigine only) after abdominoplasty and bunionectomy, respectively. (C and D) Participants included in the post hoc analysis without rescue imputation (effect of suzetrigine and ibuprofen) after abdominoplasty and bunionectomy, respectively. HB/APAP, hydrocodone bitartrate/acetaminophen; PID, pain intensity difference; SE, standard error.
Fig. 2. Mean PID over time. The figure includes participants who were randomized and received at least one dose of study drug. Participants were analyzed according to their randomized treatment. (A and B) Participants included in the prespecified analysis with rescue imputation (effect of suzetrigine only) after abdominoplasty and bunionectomy, respectively. (C and D) Participants included in the post hoc analysis without rescue imputation (effect of suzetrigine and ibuprofen) after abdominoplasty and bunionectomy, respectively. HB/APAP, hydrocodone bitartrate/acetaminophen; PID, pain intensity difference; SE, standard error.CC BY-NC-ND · PubMed Central
Fig. 3. Mean NPRS over time. The figure includes participants who were randomized and received at least one dose of study drug. Participants were analyzed according to their randomized treatment. (A and B) Participants included in the prespecified analysis with rescue imputation (effect of suzetrigine only) after abdominoplasty and bunionectomy, respectively. (C and D) Participants included in the post hoc analysis without rescue imputation (effect of suzetrigine and ibuprofen) after abdominoplasty and bunionectomy, respectively. HB/APAP, hydrocodone bitartrate/acetaminophen; NPRS, numeric pain rating scale; SE, standard error.
Fig. 3. Mean NPRS over time. The figure includes participants who were randomized and received at least one dose of study drug. Participants were analyzed according to their randomized treatment. (A and B) Participants included in the prespecified analysis with rescue imputation (effect of suzetrigine only) after abdominoplasty and bunionectomy, respectively. (C and D) Participants included in the post hoc analysis without rescue imputation (effect of suzetrigine and ibuprofen) after abdominoplasty and bunionectomy, respectively. HB/APAP, hydrocodone bitartrate/acetaminophen; NPRS, numeric pain rating scale; SE, standard error.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 72

Metadata

Authors
Bertoch, T., D’Aunno, D., McCoun, J., Solanki, D., Taber, L., Urban, J., Oswald, J., Swisher, M. W., Tian, S., Miao, X., Correll, D. J., Negulescu, P., Bozic, C., & Weiner, S. G.
Affiliations
  • Jean Brown Research (US)
  • ERG Clinical, Houston, TX, USA.
  • Atlanta Center for Medical Research (US)
  • HD Research, LLC, Bellaire, TX, USA.
  • Arizona Research Center (US)
  • OrthoNebraska, Omaha, NE, USA.
  • UC San Diego Health System (US)
  • Vertex Pharmaceuticals (United States) (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Bozic, Carmen
Venue
Anesthesiology
Published
2025-03-21
Volume
142
Issue
6
Pages
1085-1099
ISSN
  • 0003-3022 (ISSN-L)
  • 1528-1175
OpenAlex
W4408733249
Cited by
72
References
32
Citations by year
2026: 46 · 2025: 26
FWCI
67.74
Type
journal article
Language
en
Open access
Locations
  • Anesthesiology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
Keywords
suzetrigine, voltage-gated sodium channels, non-opioid analgesics, acute pain, postoperative pain, abdominoplasty, bunionectomy, opioid alternatives, pain intensity reduction, analgesic efficacy and safety, postoperative analgesia, postoperative nausea and vomiting, adverse events
MeSH terms
Acetaminophen, Adult, Aged, Double-Blind Method, Drug Combinations, Female, Humans, Hydrocodone, Male, Middle Aged, Pain Measurement, Pain, Postoperative, Postoperative Pain, Severity of Illness Index, Treatment Outcome, Analgesics, Non-Narcotic, Young Adult, Acute Pain, Voltage-Gated Sodium Channel Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials. https://app.cochat.ai/papers/10.1097/aln.0000000000005460
The paper
Bertoch, T., D’Aunno, D., McCoun, J., Solanki, D., Taber, L., Urban, J., Oswald, J., Swisher, M. W., Tian, S., Miao, X., Correll, D. J., Negulescu, P., Bozic, C., & Weiner, S. G. (2025). Suzetrigine, a Non-Opioid NaV1.8 Inhibitor for Treatment of Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. https://doi.org/10.1097/aln.0000000000005460

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.